• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.原位导管癌或微浸润性乳腺癌患者中,原发肿瘤特征在预测前哨淋巴结阳性方面的作用。
Am J Surg. 2008 Jul;196(1):81-7. doi: 10.1016/j.amjsurg.2007.08.057. Epub 2008 Apr 23.
2
Sentinel node biopsy in ductal carcinoma in situ patients.导管原位癌患者的前哨淋巴结活检
Ann Surg Oncol. 2000 Jan-Feb;7(1):15-20. doi: 10.1007/s10434-000-0015-z.
3
Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.在经粗针活检诊断为乳腺导管原位癌(DCIS)的患者中,乳房切除术治疗、前哨淋巴结活检的使用以及分期为浸润性癌的预测因素。
Ann Surg Oncol. 2014 Jan;21(1):66-73. doi: 10.1245/s10434-013-3239-4. Epub 2013 Sep 18.
4
Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?对于接受乳房切除术的导管原位癌患者,前哨淋巴结活检有必要吗?
Am Surg. 2020 Aug;86(8):955-957. doi: 10.1177/0003134820942164. Epub 2020 Aug 29.
5
Utility of intraoperative frozen section examination of sentinel lymph nodes in ductal carcinoma in situ of the breast.术中前哨淋巴结冰冻切片检查在乳腺导管原位癌中的应用。
Clin Breast Cancer. 2013 Oct;13(5):350-8. doi: 10.1016/j.clbc.2013.02.013. Epub 2013 Jun 20.
6
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.初诊为导管原位癌患者发生浸润性乳腺癌的预测因素:导管原位癌管理中前哨淋巴结活检选择性应用指南
J Am Coll Surg. 2005 Apr;200(4):516-26. doi: 10.1016/j.jamcollsurg.2004.11.012.
7
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.导管原位癌的粗针活检诊断:前哨淋巴结活检的一项指征
Curr Surg. 2005 Mar-Apr;62(2):253-7. doi: 10.1016/j.cursur.2004.09.011.
8
Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.核心活检诊断为导管原位癌患者的侵袭和腋窝淋巴结转移的预测因素:255 例分析。
Breast J. 2011 May-Jun;17(3):223-9. doi: 10.1111/j.1524-4741.2011.01069.x. Epub 2011 Mar 24.
9
Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer.导管原位癌或微浸润性乳腺癌患者前哨淋巴结阳性情况。
Am J Surg. 2006 Jun;191(6):761-6. doi: 10.1016/j.amjsurg.2006.01.019.
10
Ductal carcinoma in situ: value of sentinel lymph node biopsy.导管原位癌:前哨淋巴结活检的价值
J Surg Oncol. 2006 Oct 1;94(5):426-30. doi: 10.1002/jso.20578.

引用本文的文献

1
Meta-analysis on axillary lymph node metastasis rate in ductal carcinoma in situ with microinvasion.微浸润性导管原位癌腋窝淋巴结转移率的荟萃分析。
Cancer Med. 2024 Jun;13(12):e7413. doi: 10.1002/cam4.7413.
2
Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.大而弥漫性导管原位癌:“浸润前”疾病的潜在致命亚型。
Int J Clin Oncol. 2022 Jan;27(1):121-130. doi: 10.1007/s10147-021-02036-1. Epub 2021 Oct 7.
3
Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?利用 NSQIP 数据库分析导管原位癌患者腋窝淋巴结管理的手术趋势:我们是否遵循国家指南?
Ann Surg Oncol. 2020 Sep;27(9):3448-3455. doi: 10.1245/s10434-020-08374-0. Epub 2020 Mar 30.
4
Educational Case: Ductal Carcinoma In Situ (DCIS).教学案例:导管原位癌(DCIS)。
Acad Pathol. 2019 Nov 21;6:2374289519888727. doi: 10.1177/2374289519888727. eCollection 2019 Jan-Dec.
5
Risk factors for lymph node metastasis and the impact of adjuvant chemotherapy on ductal carcinoma in situ with microinvasion: a population-based study.淋巴结转移的危险因素及辅助化疗对伴有微浸润的导管原位癌的影响:一项基于人群的研究。
Onco Targets Ther. 2018 Dec 13;11:9071-9080. doi: 10.2147/OTT.S186228. eCollection 2018.
6
Predicting underestimation of ductal carcinoma in situ: a comparison between radiomics and conventional approaches.预测导管原位癌低估:基于放射组学和常规方法的比较。
Int J Comput Assist Radiol Surg. 2019 Apr;14(4):709-721. doi: 10.1007/s11548-018-1900-x. Epub 2018 Dec 19.
7
Characterization of circulating tumor cells in newly diagnosed breast cancer.新诊断乳腺癌中循环肿瘤细胞的特征分析
Oncol Lett. 2018 Feb;15(2):2522-2528. doi: 10.3892/ol.2017.7540. Epub 2017 Dec 6.
8
Sentinel Lymph Node Biopsy in Breast Cancer: A Clinical Review and Update.乳腺癌前哨淋巴结活检:临床综述与更新
J Breast Cancer. 2017 Sep;20(3):217-227. doi: 10.4048/jbc.2017.20.3.217. Epub 2017 Sep 22.
9
Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?微浸润性乳腺癌患者术后是否需要辅助化疗?
Cancer Biol Med. 2016 Mar;13(1):142-9. doi: 10.28092/j.issn.2095-3941.2015.0093.
10
Sentinel lymph node biopsy in patients with breast ductal carcinoma : Chinese experiences.乳腺导管癌患者前哨淋巴结活检:中国经验
Oncol Lett. 2015 Sep;10(3):1932-1938. doi: 10.3892/ol.2015.3480. Epub 2015 Jul 10.

本文引用的文献

1
Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ.肿瘤大小作为导管原位癌微浸润、浸润及腋窝转移的预测指标。
J Exp Clin Cancer Res. 2006 Jun;25(2):223-7.
2
Cancer statistics, 2006.2006年癌症统计数据。
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. doi: 10.3322/canjclin.56.2.106.
3
An update of sentinel lymph node mapping in patients with ductal carcinoma in situ.导管原位癌患者前哨淋巴结定位的最新进展。
Am J Surg. 2005 Oct;190(4):563-6. doi: 10.1016/j.amjsurg.2005.06.011.
4
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.初诊为导管原位癌患者发生浸润性乳腺癌的预测因素:导管原位癌管理中前哨淋巴结活检选择性应用指南
J Am Coll Surg. 2005 Apr;200(4):516-26. doi: 10.1016/j.jamcollsurg.2004.11.012.
5
Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ.最终诊断为导管原位癌患者的腋窝淋巴结转移情况。
Am J Surg. 2003 Oct;186(4):368-70. doi: 10.1016/s0002-9610(03)00276-9.
6
Nuclear structure in cancer tissues.癌组织中的核结构。
Surg Gynecol Obstet. 1957 Jul;105(1):97-102.
7
Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?乳腺导管原位癌(DCIS)中淋巴绘图的重要性:为何要对DCIS进行绘图?
Am Surg. 2001 Jun;67(6):513-9; discussion 519-21.
8
Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?前哨淋巴结活检:高危导管原位癌及伴有微浸润的导管原位癌患者是否需要进行该项检查?
Ann Surg Oncol. 2000 Oct;7(9):636-42. doi: 10.1007/s10434-000-0636-2.
9
Sentinel node biopsy in ductal carcinoma in situ patients.导管原位癌患者的前哨淋巴结活检
Ann Surg Oncol. 2000 Jan-Feb;7(1):15-20. doi: 10.1007/s10434-000-0015-z.
10
The biologic and clinical significance of lymphatic metastases in breast cancer.乳腺癌中淋巴转移的生物学及临床意义
Surg Oncol Clin N Am. 1996 Jan;5(1):79-104.

原位导管癌或微浸润性乳腺癌患者中,原发肿瘤特征在预测前哨淋巴结阳性方面的作用。

Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.

作者信息

Yi Min, Krishnamurthy Savitri, Kuerer Henry M, Meric-Bernstam Funda, Bedrosian Isabelle, Ross Merrick I, Ames Frederick C, Lucci Anthony, Hwang Rosa F, Hunt Kelly K

机构信息

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

出版信息

Am J Surg. 2008 Jul;196(1):81-7. doi: 10.1016/j.amjsurg.2007.08.057. Epub 2008 Apr 23.

DOI:10.1016/j.amjsurg.2007.08.057
PMID:18436181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4336928/
Abstract

BACKGROUND

We determined the incidence of positive sentinel lymph nodes (SLNs) in patients with ductal carcinoma in situ (DCIS) or microinvasive breast cancer (MIC) and the predictive factors of SLN metastasis in these patients.

METHODS

Of 4,503 patients who underwent SLN dissection between March 1994 and March 2006 at our institution, we identified those with a preoperative diagnosis or final diagnosis of DCIS or MIC. Clinicopathologic factors were examined by logistic regression analysis.

RESULTS

Of the 624 patients with a preoperative diagnosis of DCIS or MIC, 40 had positive SLNs (6.4%). Of the 475 patients with a final diagnosis of DCIS or MIC, 9 had positive SLNs (1.9%). Clinical DCIS size >5 cm was the only independent predictor of positive SLN for patients with a preoperative diagnosis and patients with a final diagnosis of DCIS or MIC. Core biopsy as the method of preoperative diagnosis and DCIS size >5 cm were independent predictors for a final diagnosis of invasive carcinoma in the 149 patients who had a preoperative diagnosis of DCIS or MIC.

CONCLUSIONS

SLN dissection for patients with a diagnosis of DCIS should be limited to patients who are planned for mastectomy or who have DCIS size >5 cm. Patients who have a core-needle biopsy diagnosis of DCIS have a higher risk of invasive breast cancer on final pathologic assessment of the primary tumor. This information can be used in preoperative counseling of patients with DCIS regarding the timing of SLN biopsy.

摘要

背景

我们确定了导管原位癌(DCIS)或微浸润性乳腺癌(MIC)患者前哨淋巴结(SLN)阳性的发生率以及这些患者SLN转移的预测因素。

方法

在1994年3月至2006年3月于我院接受SLN清扫术的4503例患者中,我们确定了术前诊断或最终诊断为DCIS或MIC的患者。通过逻辑回归分析检查临床病理因素。

结果

在术前诊断为DCIS或MIC的624例患者中,40例SLN阳性(6.4%)。在最终诊断为DCIS或MIC的475例患者中,9例SLN阳性(1.9%)。临床DCIS大小>5 cm是术前诊断患者以及最终诊断为DCIS或MIC患者SLN阳性的唯一独立预测因素。对于术前诊断为DCIS或MIC的149例患者,粗针活检作为术前诊断方法以及DCIS大小>5 cm是最终诊断为浸润性癌的独立预测因素。

结论

对于诊断为DCIS的患者,SLN清扫应仅限于计划行乳房切除术或DCIS大小>5 cm的患者。经粗针活检诊断为DCIS的患者在对原发肿瘤进行最终病理评估时发生浸润性乳腺癌的风险更高。该信息可用于术前对DCIS患者进行关于SLN活检时机的咨询。